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The counterfeiting of medicines impacts the public health and contributes to morbidity and 
mortality worldwide. Counterfeiting can occur to any medicine class of any type whether it be 
lifestyle or lifesaving medicines. With lifesaving medicines the situation is more critical, 
especially when these medicines are used in patients with non-communicable diseases (NCDs) 
who are taking multiple medicines (polypharmacy) and have multiple comorbidities. 
According to the World Health Organization, NCDs are those that cannot be cured but can be 
controlled with appropriate intake of medicines and adjustment of lifestyle factors. NCDs 
include cardiovascular diseases that are associated with 31% of deaths worldwide. 
Consequently, any defects in cardiovascular medicines, whether in physical properties or 
chemical constituents, will impact the treatment effectiveness of cardiovascular medicines. 
Thus, a substandard cardiovascular medicine would not be of less harm than a counterfeit 
medicine especially when the medicine is of low active pharmaceutical ingredients. Near-
infrared spectroscopy (NIRS) can not only identify chemical constituents in a medicinal 
formulation but also physical properties of medicines. Portable NIRS offer a further advantage 
in taking the laboratory to the sample as it measures the samples as they are with no treatment. 
Therefore, this work utilized portable NIRS for identifying counterfeit cardiovascular 
medicines focusing on both physical properties and chemical constituents. 







Medicine counterfeiting represents a global expanding problem that affects all countries 
worldwide. Counterfeit medicines are those which are deliberately or fraudulently mislabelled 
in relation to their identity or source (1,2). They may contain no active pharmaceutical 
ingredient (API), insufficient amount of API or the wrong API. On the other hand, substandard 
medicines are those who fail to match the manufacturer’s specification and/or quality 
standards. The public health impact resulting from counterfeit or substandard medicines can 
range from treatment ineffectiveness to lethal effects (3).  
Medicine counterfeiting is not exclusive to a class of medicines and can occur to all medicine 
classes whether lifestyle or lifesaving medicines (4). However, the effects with lifesaving 
medicines could be more pronounced especially among patients with non-communicable 
diseases (NCDs). NCDs are defined by the World Health Organization (WHO) as long-term 
diseases that have no permanent cure but could be controlled by modification of diet and 
lifestyle factors (5). NCDs include cardiovascular diseases (CVDs), diabetes, respiratory 
diseases and cancer. CVDs are diseases associated with the heart or blood vessels and 
contribute to morbidity and mortality worldwide (6). According to the WHO, CVDs contribute 
to 31% of global deaths. Patients with CVDs often have multiple morbidities and take multiple 
medicines and that could result in drug-drug interactions or drug-disease interactions (7).  
Subsequently, having the wrong API or the wrong dose in a cardiovascular medicine can 
interfere not only with the treatment effectiveness but also with the adverse effects, drug-drug 
interactions and drug-disease interactions. CV medicines could be encountered anywhere 
across the supply chain including patients’ homes, pharmacies and medicines. Therefore, a 
portable approach that carries the laboratory to the sample would be ideal (8,9), especially 
where a life-threatening situation is encountered. Portable near infrared spectroscopy (NIRS) 
offers the advantage of being mobile, rapid and non-destructive and this is ideal in medicine 
authentication (10, 11). NIRS has a further advantage over other techniques in not only 
detecting the chemical constituents of a sample but also the physical properties that are 
important for spotting a counterfeit or substandard medicine especially in cases of organized 
crime where a medicine of the sample source could be distributed in different countries 
worldwide (12).  
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Therefore, this work aimed to evaluate portable NIRS for authenticating cardiovascular 
medicines obtained from different countries worldwide. Moreover, the work further assessed 
the potential of portable NIRS for detecting differences in physical properties among authentic 
products of different manufacturers.  
 
Experimental 
A total of 35 individual products of eight different cardiovascular medicines were evaluated in 
this study (Table 1). Reference products were purchased from the UK; whereas, test products 
were purchased from eight different countries: Australia, Egypt, France, India, Syria, Turkey 
and the UK. The medicines were of five pharmacological classes and were intended for three 
cardiovascular conditions being antiarrhythmic, anticoagulant and antihypertensive agents. 
The pharmacological classes of the medicines were angiotensin converting enzyme inhibitor 
(n = 2), angiotensin receptor blockers (n = 3), beta blockers (n = 2), P2Y12 platelet inhibitor 
(n = 1). Angiotensin converting enzyme inhibitors used were captopril and enalapril and 
angiotensin receptor blockers were losartan, olmesartan and valsartan. The two beta-blockers 
used were atenolol and propranolol. In addition the P2Y12 platelet inhibitor used was 
clopidogrel. The concentration of the API in the measured medicines varied in the range of 8.4 
– 48.4% m/m. 
The aforementioned products were tablets and were measured ‘as received’ from both sides by 
rotating and/or flipping the tablet after each measurement using the PerkinElmer Spectrum 
Two N™ FT-NIR spectrometer with the Near-Infrared Reflectance Module (NIRM). Each 
spectrum was the sum of 32 scans over the range of 10000 – 4000 cm-1.  
NIR spectra were exported into Matlab 2014b where spectral pre-treatment and treatment were 
applied. Spectral pre-treatment algorithms used were multiplicative scatter correction-second 
derivative (MSC-D1) and spectral treatment algorithms used were correlation in wavenumber 
space (CWS) and principle component analysis (PCA). For CWS method, the correlation 
coefficient (r) value of each test product was compared against the reference product. CWS 
method gave r values in the range of -1 to +1 where -1 indicated that the compared products 
were completely dissimilar and +1 indicated they were identical. The threshold taken for 
authenticity was r value above 0.95. On the other hand, PCA scores allowed visualisation of 
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clusters among reference and test products. Thus, the first two PCA scores of reference and 
test products were plotted and clusters of the products were compared. 
 
Results and Discussion 
The evaluated medicinal products were chosen on the basis of being used for critical 
cardiovascular conditions including arrhythmia, hypertension, ischemic heart disease and 
myocardial infarction. As patients with CVDs often have polypharmacy and suffer from 
multiple comorbidities, substandard/counterfeit medicines encountered will negatively impact 
the treatment outcome. It is also noteworthy to mention that the medicinal products had wide 
variations in colours, shapes and percentage of API. The percentage of API in the 
aforementioned medicinal products was in the range of 8.14 – 48.4% m/m. The number of 
excipients in the medicinal products ranged between three and 12 excipients. Yet, the most 
common excipients often encountered were lactose, maize starch and microcrystalline 
cellulose (MCC). Having the excipients alongside the API was key information for 
authenticating the medicinal products as part of the physicochemical fingerprinting of the 
products. 
NIRS offered the advantage of inspecting the physicochemical properties of medicinal products 
non-destructively. Having a portable NIR device offered further benefits in mobility so the 
instruments could be carried to the sample without the need for distinctive laboratory settings. 
Additionally, obtained a spectral signature required few seconds to minutes. The software 
allowed spectra to be exported to external software where offline analysis could be applied.  
 
Spectral evaluation of reference products 
In this respect, Often spectra matched their main excipient especially among products with low 
% m/m of API. Hence, propranolol has lowest percentage of API (8.14% m/m) among the 
evaluated medicinal products and gave high r values for lactose, hypromellose and MCC that 
corresponded to 0.82, 0.76 and 0.72 respectively. However, none of the aforementioned values 
could be considered as they were below the threshold (i.e. 0.95). High r values were also 
observed for additional products with low % m/m of APIs (< 20%). In this respect, captopril 
(API of 13.9% m/m) and olmesartan (API of 13.2% m/m) gave r values of 0.71 and 0.7 for 
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lactose, and 0.79 and 0.88 for MCC respectively. As the % m/m of API in a product increased 
the r values against the excipients decreased but high r values were still observed for some of 
the excipients.  Hence, losartan, clopidogrel and atenolol had % m/m of APIs of 22.1, 24.1 and 
29.8% m/m respectively. Losartan gave rvalues of 0.79, 0.74 and 0.84 against hypromellose, 
lactose monohydrate and MCC. Clopidogrel that had higher % m/m of API showed lower r 
values for the aforementioned three excipients that were 0.71, 0.66 and 0.77 respectively. 
Atenolol had very low r values against all excipients that were below 0.51. Likewise, valsartan 
had 48.4% of API and gave r values below 0.65 for all excipients. 
As the reference medicinal products had common excipients, CWS was applied to observe any 
type I or type II errors that could be encountered in identification of the aforementioned 
medicines. Type I error was encountered when a medicinal product was misidentified as itself 
(i.e. gave r value < 0.95 against its reference spectra) and type II error was encountered when 
a medicinal product was misidentified as another product (i.e. gave r value > 0.95 against 
another product’s spectra).  In this respect, no type I error was observed for individual tablets 
of each reference product. However, type II error was observed for propranolol spectra that 
were identified as olmesertan (r = 0.95). This could be due to the common excipients among 
both products. 
 
Tracking authenticity of products 
Subsequently, CWS was adopted for evaluating the authenticity of test products. In this respect, 
the spectra of the test medicinal products were compared against the reference products and 
actual/potential constituents within each product (Table II). Only one test product was 
evaluated for atenolol, captopril and enalapril but the three products passed against the 
reference and gave r values of 0.9999. On the other contrary, match failures were seen among 
losartan, propranolol and clopidogrel test products and that could indicate the presence of 
counterfeit or substandard products. Two out of three losartan test products failed against the 
authentic reference and gave r values of 0.9189 and 0.8349. Only one propranolol product (P3) 
passed with r value of 0.9503. The remaining propranolol products gave r values in 0.8917 – 
0.9111. Only four clopidogrel products passed and gave r values in the range of 0.9859 – 
0.9949. The remaining clopidogrel products that failed gave r values in the range of 0.7016 – 
0.9365. Two of the failed clopidogrel products (P2 and P3) had close r values against the 
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reference product (0.7016 and 0.7226) and similar r values against each other (r = 0.9746). 
When the spectrum of P3 was compared to the authentic product spectra, they were quiet 
dissimilar (Figure 2). It is noteworthy to mention that P3 spectrum showed a peak at 7196 cm-
1 corresponding to talc that was not an excipient in reference clopidogrel product (Figure 2). 
The r value matches among clopidogrel products was also reflected in the correlation map that 
compared the r values of the 13 different clopidogrel products. Figure 3 shows the details of 
the correlation map with colours ranging from dark blue (r values 0.64 – 0.73), light blue (0.74-
0.8), green (0.8 – 0.85), yellow (0.85 – 0.89), orange (0.89 – 0.95) and dark red (0.95 – 1). 
Therefore, the darkest colour indicated highly similar products and showed that the products 
had the same matrix of APIs and excipients. Not only high matches were observed among the 
two potential counterfeit clopidogrel products (i.e. P2 and P3), but also among authentic 
products P4 – P6 had r values above 0.99 against each other and against P1 (reference product). 
Also, P8 had r values above 0.98 against the aforementioned authentic products and that 
indicated authenticity of the products relating to their physicochemical properties. 
 
Tracing physicochemical properties of products 
Physicochemical properties among the products were further confirmed when PCA was applied 
to the products with authentic and potential counterfeit/substandard samples. Figure 4 shows 
the PCA scores plots of propranolol, clopidogrel, losartan and valsartan. For clopidogrel, the 
PC scores reflected the results obtained by the CWS method where authentic products’ scores 
were grouped together and separated from counterfeit products’ scores. It is noteworthy to 
mention that the PCA results did not always match the CWS method and this could be due to 
the different manufacturing sources of the individual products and/or suitability of the PCA 
model. Two clusters were seen for propranolol products where individual scores of two 
products were seen in two clusters and this could be due to lack of accuracy of the model. For 
instance, all valsartan products were confirmed authentic using CWS method (r values between 
0.9965 – 0.9988) but they showed three distinct clusters when measured using PCA method 
and this could indicate different manufacturing sources. Three distinct clusters were also seen 
among the three losartan products which were obtained from three sources i.e. India, Lebanon 
and the UK. Hence, PCA method showed classified spectra according to variances rather than 
comparing the whole spectra taking into account both physical and chemical differences 
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reflected within spectra. Therefore, PCA on its own may not indicate authenticity where 
different manufacturing sources of products were involved. 
 
Conclusion 
Portable NIRS offered a rapid, mobile and cost-effective method for authenticating 
cardiovascular medicines and that could serve as alternative to laboratory-based instruments 
where different laboratory settings are involved. CWS method was successful in authenticating 
a cardiovascular product and raising alertness for potential counterfeit and/or substandard 
products. However, PCA showed to be complementary to CWS in authenticating products 
where it uncovered detailed variability relating to physicochemical among individual products 
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N: number of products that include one reference product for each medicine.  
 
Table II. Correlation coefficient values of test products against their corresponding reference 
products 
Product Product Source r value Result 
Atenolol P1 Lebanon 0.9999 P 
Propranolol P1 UK 0.9111 F 
P2 UK 0.8922 F 







Clopidogrel P1 Syria 0.9129 F 
P2 Egypt 0.7016 F 
P3 France 0.7226 F 
P4 France 0.9931 P 
P5 Turkey 0.9907 P 
P6 UK 0.9949 P 
P7 Lebanon 0.7858 F 
P8 Australia 0.9859 P 
P9 Syria 0.9052 F 
P10 India 0.9365 F 
P11 India 0.7838 F 
P12 India 0.9149 F 











Iron oxide (yellow, red) 
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Iron oxide (yellow, 








Captopril P1 Lebanon 0.9999 P 
Enalapril P1 Lebanon 0.9999 P 
Losartan P1 UK 0.9189 F 
P2 Lebanon 0.8349 F 
Olmesartan P1 India 0.9999 P 
Valsartan P1 Lebanon 0.9988 P 
P2 Turkey 0.9965 P 
P3 Turkey 0.9973 P 
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Figure 1 MSC-D1 treated NIR spectra of (a) lactose, (b) maize starch, (c) MCC, (d) talc, (e) 
atenolol, (f) propranolol, (g) clopidogrel, (h) captopril, (i) enalapril, (j) losartan, (k) 
olmesartan and (l) valsartan measured using the PerkinElmer Spectrum Two N™ FT-NIR 





Figure 2 MSC-D1 treated NIR spectra of clopidogrel reference product (blue), authentic test 
product (red, r = 0.7227) and counterfeit test product (magenta, r = 0.9931) measured using 
the PerkinElmer Spectrum Two N™ FT-NIR spectrometer with the Near-Infrared 





Figure 3 Correlation map of clopidogrel products including reference product and test 
products being P1 (Syria), P2 (Egypt), P3 (France), P4 (France), P5 (Turkey), P6 (UK), P7 
(Lebanon), P8 (Australia), P9 (Syria), P10 (India), P11 (India) and P12 (India) respectively. 






Figure 4 PCA scores plot of the MSC-D1 NIR spectra of authentic (blue) and test products of 
(a) propranolol, (b) clopidogrel, (c) losartan and (d) valsartan medicines measured using the 
PerkinElmer Spectrum Two N™ FT-NIR spectrometer with the Near-Infrared Reflectance 
Module (NIRM). 
 
